Menu

Fat’s Influence on Cancer

Researchers at the annual American Association for Cancer Research meeting discuss the roles of adipose tissue and inflammation in the growth and spread of tumors.

Apr 3, 2017
Jef Akst

JEF AKSTObesity is the leading preventable cause of cancer in the U.S. Extra body fat not only increases one’s risk of developing cancer, it is also associated with poorer prognosis. In November 2014, researchers published a paper in The Lancet estimating that a half-million new cancer diagnoses each year are related to patients’ weights, and some 10 percent to 15 percent of cancer deaths are attributed to obesity, noted Mikhail Kolonin of the University of Texas Health Science Center at Houston, during a session yesterday (April 2) at the annual meeting for the American Association for Cancer Research (AACR) in Washington, DC.

For many years, these phenomena were “considered effects of diet or lifestyle, but as we’ve learned more about the process, it’s become clear that the fat tissue itself is very important,” Kolonin said. His group has found, for example, that stromal cells from the adipose tissue localized to tumors in colorectal and prostate cancers, and depletion of the cells suppressed tumor growth in mice

Details of how body fat can influence cancer biology remain murky, but a key link is inflammation. Andrew Dannenberg of Weill Cornell Medicine in New York City and colleagues found that presence of crown-like structures (CLSs)—which form as macrophages surround dead or dying adipocyte in the fat tissue, resulting in increased cytokine production and increased lipolysis—was higher in the breasts of overweight and obese young women than in their healthy-weight counterparts, as well as evidence that such white adipose tissue (WAT) inflammation linked metabolic syndrome with worse prognosis in breast cancer patients. Dannenberg and colleagues have further found that WAT inflammation in the breast results in notable transcriptomic changes, including the downregulation of genes involved in branched chain amino acid catabolism and the upregulation of aromatase.

Such inflammation is asymptomatic, however, and is thus considered “clinically occult,” Dannenberg explained during his talk at AACR. “The take-home message is that occult breast inflammation is an independent prognositic biomarker.” Such inflammation is found in women with normal body mass indices (BMIs) and is associated with the same gene-expression difference seen in obese and overweight women, he added, so a normal BMI may not be enough for a doctor’s thumbs up (Breast Cancer Res, 19:8, 2017; Cancer Prev Res, in press). “The finding of elevated aromatase in these normal sized women is almost certainly going to be associated with an increased risk of breast cancer,” Dannenberg said. “If we can make the diagnosis early enough, there might be the opportunity to intervene.”

If obesity does indeed create a microenvironment that aids tumor growth, the question arises about whether weight loss can help fix the problem. “Obesity can cause more aggressive tumor onset,” said Liza Makowski of the University of North Carolina Gillings School of Global Public Health. “What happens when we reverse that?”

Work in mice has suggested that this is possible. In Makowski’s work, for example, formerly obese mice that had lost weight experienced slower tumor growth comparable to that of lean mice (Frontiers, doi:10.3389/fonc.2014.00175, 2014; unpublished work). “Even though they were obese they reverted their phenotype essentially back to the lean,” Makowski said.

In looking for which cells are important in mediating the permissive tumor microenvironment in obese individuals, Makowski and colleagues have focused on macrophages, which, depending on their subtype, can either promote or inhibit inflammation. By manipulating the cells’ metabolisms, preventing the breakdown of glucose, Makowski’s team has effectively encouraged the production of more anti-inflammatory macrophages, which tend to rely on fatty acid metabolism. “[We] can metabolically reprogram the microenvironment by blocking glucose metabolism, which blunted tumor progression,” she said.

See “Breaking the Cancer-Obesity Link

See “Obesity-Cancer Link Detailed

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.